InpharmD’s Post

I want to make sure everyone is aware of the great clinical drug information resources available at no cost such as the landmark QWINT-2 trial summary below. Follow InpharmD for more!

Another milestone for PolTREG. We are announcing positive results of a long-term safety and efficacy study of PTG-007 in early-onset type-1 diabetes (T1D). “At PolTREG, we believe that PTG-007 has the potential to prevent type-1 diabetes, freeing patients of the life-long burden of having to take frequent insulin injections, and the serious long-term complications of the disease. The results of this study are an important step in that direction,” said Prof Piotr Trzonkowski, PolTREG S.A. Chief Executive Officer.   Here are the main findings, found over a period of up to 12 years during which patients were monitored: ☑ Patients who received PTG-007 continued to secrete insulin, while untreated patients in the control group did not, ☑ Safety measures showed no significant difference in the health status of patients who received Treg therapy compared to the control group, ☑ The duration of disease remission was significantly longer in patients who received PTG-007 compared to the control group.   No other company currently can show similar long-term safety results of Treg therapy in T1D. This is a significant competitive advantage, and paves the way for the launch of a pivotal Phase 2/3 study of PTG-007 – a final step before seeking market authorization.   Read our press release here: https://lnkd.in/dNEyDRK7   #biotech #biotechnology #celltherapy #cellandgenetherapy #autoimmunedisease #diabetes #type1diabetes

Your patients can now say goodbye to multiple daily injections and enjoy the freedom of more convenient, discreet, and injection-free mealtime insulin dosing.* Learn more at myceqursimplicity.com. *Bergenstal R, Peyrot M, Dreon D, Aroda V, Bailey T, Brazg R, Frias J, Johnson M, Klonoff D, Kruger D, Ramtoola S, Rosenstock J, Serusclat P, Weinstock R, Naik R, Shearer D, Zraick V, Levy B on behalf of the Calibra Study Group. 2019. Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. Diabetes Technology and Therapeutics 21 (5):1-13. #CeQurSimplicity #MealtimeInsulin #DiabetesManagement #InsulinDelivery #SimplifyDiabetes #Diabetes

Important long-term clinical data from PolTREG S.A. using #Treg #celltherapy in #type1diabetes.

Time in range was heavily discussed at #EASD2024—the European Association for the Study of Diabetes’ annual conference. We’ve put our top 3 takeaways below 👇 Time in range helps researchers better understand new treatments: time in range was presented as a marker of efficacy for two different trailblazing drugs—combined insulin icodec and semaglutide, and sotagliflozin. CGM has benefits for everyone with diabetes: new evidence shows that CGM use leads to significant improvements in glucose management and reduced hospitalization rates in people with type 2 diabetes—regardless of their treatment regimen! Time in range is associated with decreased diabetes complications: Even more evidence has come out that supports the relationship between increased time in range and a decrease in diabetes complications in both people with type 1 and type 2 diabetes. Read more about these exciting breakthroughs below—and make sure you’re signed up for the time in range coalition newsletter so you can get news like this straight to your inbox at https://lnkd.in/edxeSXiK. 

New findings show that tirzepatide, an injectable weight-loss drug sold under the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period compared with a placebo. The multi-institutional study, led by Dr. Louis Aronne of Weill Cornell Medicine and NewYork-Presbyterian Hospital, showed that after 176 weeks of treatment, only 1.3% of patients who were both obese and prediabetic and took the drug in any of three doses, progressed to type 2 diabetes. Among patients taking a placebo, 13.3% progressed to type 2 diabetes. Full story: https://bit.ly/4eQgN22

Insulin dose management in children with new-onset type 1 diabetes may be challenging as the spectrum of insulin sensitivity vs resistance can be broad and depends on biological and clinical features, sometimes unexpected (e.g. sarcopenia). In the INSENODIAB study lead by Dr Beckers, our team recently described the factors influencing insulin daily dose at diagnosis and proposed a formula as a tool for insulin prescription with the aim of speeding up glycemic control in these patients. Please find further details on the research here: https://lnkd.in/eqAuPbQQ.

𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐌𝐢𝐥𝐞𝐬𝐭𝐨𝐧𝐞 𝐢𝐧 𝐓𝐲𝐩𝐞 𝟐 𝐃𝐢𝐚𝐛𝐞𝐭𝐞𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡! Biomea Fusion has unveiled positive topline results from the Phase II COVALENT-111 study of icovamenib, a potential game-changer for patients with type 2 diabetes (T2D). This trial demonstrated clinically meaningful HbA1c reductions, with the strongest results in patients with severe insulin deficiency. 𝐊𝐞𝐲 𝐨𝐮𝐭𝐜𝐨𝐦𝐞𝐬: ✔️ Mean HbA1c reduction of 1.47% in the most insulin-deficient patients. ✔️ Well-tolerated safety profile with no serious adverse events. ✔️ First-in-class potential with a unique mechanism targeting menin inhibition. These findings pave the way for advancing icovamenib as a transformative option in diabetes care. With further insights expected in 2025, the future of T2D management looks brighter than ever! 📢 𝐉𝐨𝐢𝐧 𝐁𝐢𝐨𝐦𝐞𝐚’𝐬 𝐢𝐧𝐯𝐞𝐬𝐭𝐨𝐫 𝐰𝐞𝐛𝐜𝐚𝐬𝐭 𝐫𝐞𝐩𝐥𝐚𝐲 𝐭𝐨 𝐝𝐢𝐯𝐞 𝐝𝐞𝐞𝐩𝐞𝐫 𝐢𝐧𝐭𝐨 𝐭𝐡𝐞 𝐫𝐞𝐬𝐮𝐥𝐭𝐬: https://lnkd.in/gSG38VFe #diabetescare #clinicaltrials #innovationinhealth #hba1c #digitalhealth

Insurers choosing not to cover #Ozempic or #Wegovy might be on to something; Over a two-year period, data from Prime Therapeutics (a PBM), shows no reduction in obesity-related medical events --- think heart attacks, strokes, and type 2 diabetes diagnosis. Prescriptions for hypertension and high cholesterol also remained flat. And, only 1 in 4 patients remains on either drug two years later. In this study at least, no sufficient data proved the drugs led to better health outcomes.

🚨Proof of concept study looking at Terzepitide use in patients with Type 1 Diabetes with BMI >27. 💥Impressive Results:💥 ⬇️ HbA1c by 0.59% at 8 months ⬆️ time in range, with greatest increase in Time in Tight Range (70-140). ⬇️ insulin use by >20 units ⬇️ body weight body weight by >10% at 8 months “Conclusions: Tirzepatide significantly reduced HbA1c and body weight in adults with T1D. A randomized controlled trial is needed to establish efficacy and safety of this drug in T1D.” ‼️Important to note‼️Patients were using CGM during the trial which helps to identify and prevent hypoglycemia events. #type1diabetes #cgm #obesitytreatment https://lnkd.in/ghYPsFDq